Does ctDNA add value to current prognostic markers for identifying high-risk patients?
Lymphoma Hub7 Jan 2021

Does ctDNA add value to current prognostic markers for identifying high-risk patients?

This is the third episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Alex Herrera, City of Hope Comprehensive Cancer Center, Duarte, US, Does ctDNA add value to current prognostic markers for identifying high-risk patients?


ctDNA can be a useful tool for identifying residual disease after the initiation of treatment, and it can also be used as a prognostic factor for outcome with a particular treatment.


In this podcast, Herrera discusses the results of a phase Ib/II study evaluating the prognostic value of ctDNA for identifying patients with relapsed/refractory diffuse large B-cell lymphoma, receiving polatuzumab + bendamustine and rituximab versus bendamustine and rituximab alone, at higher risk for disease progression.


Hosted on Acast. See acast.com/privacy for more information.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(53)

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

20 Aug 23min

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas S...

12 Aug 27min

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee mem...

12 Aug 12min

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel ...

21 Juli 8min

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We...

16 Juli 10min

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating za...

10 Juli 26min

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL?

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, W...

1 Juli 5min

Annual oncology meeting | Key highlights in lymphoma

Annual oncology meeting | Key highlights in lymphoma

During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount ...

22 Juni 11min

Populärt inom Utbildning

historiepodden-se
det-skaver
rss-bara-en-till-om-beroende-medberoende
nu-blir-det-historia
not-fanny-anymore
roda-vita-rosen
allt-du-velat-veta
harrisons-dramatiska-historia
rss-viktmedicinpodden
rikatillsammans-om-privatekonomi-rikedom-i-livet
johannes-hansen-podcast
sa-in-i-sjalen
rss-max-tant-med-max-villman
i-vantan-pa-katastrofen
rss-foraldramotet-bring-lagercrantz
rss-ar-det-rimligt
sektledare
rss-sjalsligt-avkladd
sex-pa-riktigt-med-marika-smith
rss-traningsklubben